Compare SFBC & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFBC | TNXP |
|---|---|---|
| Founded | 1953 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.7M | 88.0M |
| IPO Year | 2012 | 2008 |
| Metric | SFBC | TNXP |
|---|---|---|
| Price | $46.60 | $5.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $44.25 |
| AVG Volume (30 Days) | 2.0K | ★ 965.4K |
| Earning Date | 11-06-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.88% | N/A |
| EPS Growth | 53.89 | ★ 91.75 |
| EPS | ★ 1.59 | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $319.65 |
| Revenue Next Year | N/A | $101.60 |
| P/E Ratio | $28.18 | ★ N/A |
| Revenue Growth | N/A | ★ 29.85 |
| 52 Week Low | $40.68 | $5.01 |
| 52 Week High | $49.21 | $20.56 |
| Indicator | SFBC | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 53.51 | 15.63 |
| Support Level | $45.18 | N/A |
| Resistance Level | $46.77 | $12.99 |
| Average True Range (ATR) | 0.86 | 0.49 |
| MACD | 0.34 | -0.03 |
| Stochastic Oscillator | 63.54 | 8.27 |
Sound Financial Bancorp Inc operates as the holding company for Sound Community Bank that provides traditional banking and other financial services for individuals and businesses. It attracts retail and commercial deposits from the public and invests those funds, along with borrowed funds, in loans secured by first and second mortgages on one-to-four-family residences including home equity loans and lines of credit, commercial and multifamily real estate, construction and land, consumer and commercial business loans. The bank also offers secured and unsecured consumer loan products, including manufactured home loans, floating home loans, automobile loans, boat loans, and recreational vehicle loans.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.